Metabolic Radiomics for Pretreatment 18F-FDG PET/CT to Characterize Locally Advanced Breast Cancer: Histopathologic Characteristics, Response to Neoadjuvant Chemotherapy, and Prognosis-Reference-Cited by-同舟云学术

Metabolic Radiomics for Pretreatment 18F-FDG PET/CT to Characterize Locally Advanced Breast Cancer: Histopathologic Characteristics, Response to Neoadjuvant Chemotherapy, and Prognosis

Published:2017-05-08 Issue:1 Volume:7 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Ha Seunggyun^ORCID,Park Sohyun,Bang Ji-In,Kim Eun-Kyu,Lee Ho-Young

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-017-01524-7.pdf

Reference39 articles.

1. Kuerer, H. M. et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. Journal of Clinical Oncology 17, 460–469 (1999).

2. Groheux, D., Espié, M., Giacchetti, S. & Hindié, E. Performance of FDG PET/CT in the clinical management of breast cancer. Radiology 266, 388–405 (2013).

3. Yoon, H.-J. et al. Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from 68Ga-RGD PET/CT and 18F-FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging 41, 1534–1543 (2014).

4. Groheux, D. et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. European Journal of Nuclear Medicine and Molecular Imaging 38, 426–435 (2011).

5. Groheux, D. et al. Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype. Radiology 277, 358–371 (2015).

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research on the application of radiomics in breast cancer: A bibliometrics and visualization analysis;Medicine;2024-08-30

2. 18F-Fluorodeoxyglucose Positron Emission Tomography-Based Risk Score Model for Prediction of Five-Year Survival Outcome after Curative Resection of Non-Small-Cell Lung Cancer;Cancers;2024-07-12

3. Respective contribution of baseline clinical data, tumour metabolism and tumour blood-flow in predicting pCR after neoadjuvant chemotherapy in HER2 and Triple Negative breast cancer;EJNMMI Research;2024-07-04

4. Baseline [18F]FDG PET/CT and MRI first-order breast tumor features do not improve pathological complete response prediction to neoadjuvant chemotherapy;European Journal of Nuclear Medicine and Molecular Imaging;2024-06-26

5. Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group;JCO Precision Oncology;2024-06